Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
CytoMed Therapeutics Limited ( (GDTC) ) has provided an update.
On December 8, 2025, CytoMed Therapeutics Limited announced a Memorandum of Understanding with Universiti Malaya Medical Centre in Malaysia to establish a multi-site, first-in-human Phase I clinical trial for its patented donor-derived gamma delta T cell product candidate. This trial aims to evaluate the safety and efficacy of these cells in cancer patients who have exhausted standard treatments. This collaboration is expected to provide an affordable immunotherapy option for patients with limited treatment alternatives, leveraging the natural ability of T cells to detect and kill cancer cells. The initiative complements CytoMed’s ongoing trials in Singapore and reflects its commitment to advancing clinical innovation in Southeast Asia.
The most recent analyst rating on (GDTC) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on CytoMed Therapeutics Limited stock, see the GDTC Stock Forecast page.
Spark’s Take on GDTC Stock
According to Spark, TipRanks’ AI Analyst, GDTC is a Neutral.
GDTC’s overall stock score is primarily impacted by its poor financial performance, characterized by declining revenues and persistent losses. Technical analysis further indicates bearish momentum, while valuation metrics highlight ongoing financial struggles with a negative P/E ratio and no dividend yield.
To see Spark’s full report on GDTC stock, click here.
More about CytoMed Therapeutics Limited
CytoMed Therapeutics Limited is a Singapore-based clinical stage biopharmaceutical company that develops novel, affordable donor-derived cell-based immunotherapies for treating a broad range of cancers, including both blood and solid tumors. The company was incorporated in 2018 and spun off from the Agency for Science, Technology and Research (A*STAR), Singapore’s leading public sector research and development agency. CytoMed focuses on harnessing proprietary technologies, such as gamma delta T cell and iPSC-derived gamma delta Natural Killer T cell, to create allogeneic immunotherapies inspired by the clinical success of existing CAR-T therapies.
Average Trading Volume: 113,997
Technical Sentiment Signal: Sell
Current Market Cap: $20.77M
For detailed information about GDTC stock, go to TipRanks’ Stock Analysis page.